Thursday, April 25, 2024, Washington, DC, 6:00 AM – 7:30 AM Eastern Time

What I Tell My Patients: Integrating New Research Information into Current Clinical Care

A Complimentary NCPD Hybrid Symposium Series Held During the 49th Annual ONS Congress

Endometrial Cancer

 
Location
Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Program Schedule — Eastern Time
5:30 AM – 6:00 AM — Registration
6:00 AM – 7:30 AM — NCPD Breakfast Meeting

Meeting Room
Independence Ballroom (Meeting Level 4)

This event will also be webcast live.
Please see Registration tab for details.

There is no registration fee for this event. For the in-person symposium in Washington, DC, preregistration is required as seating is limited.  
 
Faculty
Jennifer Filipi, MSN, NP
Department of Gynecologic Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Kathryn M Lyle, MSN, WHNP-BC, AGNP-C
Nurse Practitioner
Division of Gynecologic Oncology
The University of Alabama at Birmingham
Birmingham, Alabama

David M O'Malley, MD
Director and Professor
Division of Gynecologic Oncology in Obstetrics
and Gynecology
John G Boutselis Chair in Gynecologic Oncology
The Ohio State University and The James Comprehensive Cancer Center
Columbus, Ohio


Shannon N Westin, MD, MPH, FASCO, FACOG Professor
Medical Director, Gynecologic Oncology Center
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Meeting space has been assigned to provide a satellite symposium supported by Eisai Inc, GSK, and Merck during the Oncology Nursing Society’s (ONS) 49th Annual Congress, April 24-28, 2024 in Washington, DC. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Eastern Time
5:30 AM – 6:00 AM — Registration
6:00 AM – 7:30 AM — NCPD Breakfast Meeting

What I Tell My Patients About ...

The Incidence and Biology of Endometrial Cancer (EC)

  • Incidence and prognosis of EC in the United States and the rest of the world
  • Current appreciation of various molecular subtypes of EC and implications for prognosis and current management
  • Frequency of microsatellite instability (MSI)/mismatch repair (MMR) deficiency in patients with EC
  • Optimal timing of and approach to MSI/MMR assessment

The Rationale for the Use of Immune Checkpoint Inhibitors for EC

  • Mechanism of action of anti-PD-1/PD-L1 antibodies
  • Similarities and differences among different currently available anti-PD-1/PD-L1 antibodies
  • Published efficacy and safety data with anti-PD-1/PD-L1 antibody monotherapy for MSI-high (MSI-H)/MMR-deficient (dMMR) recurrent EC
  • Optimal integration of pembrolizumab and dostarlimab into the care of patients with recurrent MSI-H/dMMR EC

First-Line Therapy for Primary Advanced or Recurrent EC

  • Historical role of and outcomes achieved with chemotherapy as first-line treatment for patients with primary advanced or recurrent EC
  • Biological rationale for the evaluation of anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with EC
  • Similarities and differences among the Phase III RUBY, NRG-GY018 and AtTEnd trials evaluating dostarlimab, pembrolizumab and atezolizumab, respectively, in combination with chemotherapy as first-line treatment for patients with primary advanced or recurrent EC
  • Key efficacy findings from the RUBY, NRG-GY018 and AtTEnd trials; outcomes reported in the MSI-H/dMMR and microsatellite-stable (MSS)/MMR-proficient (pMMR) cohorts
  • Recent FDA approval of dostarlimab in combination with carboplatin and paclitaxel, followed by single-agent dostarlimab, for primary advanced or recurrent dMMR/MSI-H EC; optimal integration into current management

The Potential Benefits of PARP Inhibition Combined with Immunotherapy for Advanced EC

  • Mechanism of antitumor activity of PARP inhibitors and biological rationale for their investigation in EC; potential therapeutic synergy between PARP inhibitors and immune checkpoint inhibitors (ICIs)
  • Key efficacy findings from the Phase III DUO-E trial evaluating first-line durvalumab in combination with chemotherapy followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent EC
  • Similarities and differences between the designs of the DUO-E trial and part 2 of the RUBY trial; recently presented data with maintenance dostarlimab/niraparib in RUBY part 2
  • Potential role of anti-PD-1/PD-L1 antibodies in combination with PARP inhibitors in the future care of patients with EC

Tolerability and Other Practical Considerations with Anti-PD-1/PD-L1 Antibodies Alone or in Combination with Chemotherapy or a PARP Inhibitor

  • Pathophysiology, incidence and spectrum of immune-mediated and other adverse events (AEs) observed with anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy or a PARP inhibitor
  • Recommended monitoring and management paradigm for immune-related and other AEs with ICIs for gynecologic cancers
  • Strategies to discern whether toxicities relate to chemotherapy, a PARP inhibitor, immune checkpoint inhibition or combinations of these agents
  • Role of rechallenge for patients for whom ICI therapy has been held due to immune-mediated toxicity
  • Relative and absolute contraindications to anti-PD-1/PD-L1 antibody therapy; role, if any, in treatment for patients with preexisting autoimmune conditions or a history of solid organ transplant

The Role of Lenvatinib/Pembrolizumab in the Management of pMMR Metastatic EC

  • Biological rationale for combining ICIs with agents targeting the VEGF pathway in EC
  • Major findings, including overall survival data, supporting the use of lenvatinib in combination with pembrolizumab for patients with advanced pMMR EC with disease progression after prior systemic therapy
  • Optimal integration of pembrolizumab/lenvatinib into current EC management algorithms
  • Recent announcement of failure of the Phase III LEAP-001 trial evaluating lenvatinib/pembrolizumab in the up-front setting; implications for current practice and future research

Toxicities with Lenvatinib/Pembrolizumab

  • Incidence, severity, timing and management of AEs observed in patients with EC receiving lenvatinib/pembrolizumab, such as hypertension, gastrointestinal issues, weight loss and hand-foot syndrome
  • Approaches to encourage adequate nutrition among patients receiving the combination of lenvatinib and pembrolizumab
  • Initial dosing and dose-modification strategies for pembrolizumab/lenvatinib for EC; available data exploring the effect of lenvatinib dose reductions on antitumor activity
  • Strategies to determine the cause of toxicities that could stem from either lenvatinib or pembrolizumab

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of endometrial cancer (EC).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate the importance of microsatellite instability (MSI) and mismatch repair (MMR) deficiency assessment for patients with EC, and adapt current testing practices to optimally identify individuals with these genetic abnormalities.
  • Appreciate findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy for newly diagnosed advanced or recurrent EC, and consider the current and future role of these novel strategies in the care of patients with MSI-high/MMR-deficient and microsatellite-stable/MMR-proficient disease.
  • Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for advanced or metastatic EC, and consider the potential role of this novel strategy in clinical practice.
  • Review the benefits observed with anti-PD-1/PD-L1 antibodies as monotherapy for MSI-high or MMR-deficient EC, and integrate these agents into the care of appropriate patients with relapsed/refractory disease.
  • Recognize available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and appropriately select patients with metastatic EC for this approach.
  • Describe the scientific justification for, published research with and current studies of novel agents and strategies for EC, and effectively prioritize clinical trial opportunities for eligible patients.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA Certification
This program will be submitted for ONCC/ILNA certification.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Filipi and Ms Lyle — No relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr O'MalleyAdvisory Committees and Consulting Agreements (Personal Fees): AbbVie Inc, Adaptimmune, Agenus Inc, Arcus Biosciences, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, Cardiff Oncology, Celcuity, Clovis Oncology, Corcept Therapeutics, Duality Biologics, Eisai Inc, Elevar Therapeutics, Exelixis Inc, F Hoffmann-La Roche Ltd, Genelux Corporation, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Imvax Inc, InterVenn Biosciences, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Laekna Therapeutics, Leap Therapeutics Inc, Luzsana Biotechnology, Merck, Mersana Therapeutics Inc, MSD, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, OncoC4, Onconova Therapeutics Inc, Regeneron Pharmaceuticals Inc, Replimune, Roche Diagnostics, R-Pharm US, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tarveda Therapeutics, Toray Industries Inc, Trillium Therapeutics Inc, Umoja Biopharma, VBL Therapeutics, Verastem Inc, Vincerx Pharma, Xencor, Zentalis Pharmaceuticals; Contracted Research (Institution Received Funds): AbbVie Inc, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Clovis Oncology, Deciphera Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Iovance Biotherapeutics, Karyopharm Therapeutics, Leap Therapeutics Inc, Merck, Mersana Therapeutics Inc, MSD, Novartis, Novocure Inc, OncoC4, OncoQuest Inc, Pfizer Inc, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Rubius Therapeutics, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tesaro, A GSK Company, Verastem Inc; Nonrelevant Financial Relationships: GOG Foundation Inc, Ludwig Institute for Cancer Research Ltd, National Cancer Institute, NRG Oncology, RTOG, SWOG. Dr WestinConsulting Agreements: AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Clovis Oncology, Eisai Inc, EQRx, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, Mersana Therapeutics Inc, NGM Biopharmaceuticals, Nuvectis Pharma Inc, pharmaand GmbH, Seagen Inc, Verastem Inc, Vincerx Pharma, Zentalis Pharmaceuticals, ZielBio; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings, Clovis Oncology, Genentech, a member of the Roche Group, GSK, Jazz Pharmaceuticals Inc, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, pharmaand GmbH, Zentalis Pharmaceuticals.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Eisai Inc, GSK, and Merck.

Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room:
Independence Ballroom (Meeting Level 4)

The Marriott Marquis Washington, DC is the headquarters hotel for the 2024 ONS Congress and is connected to the Walter E Washington Convention Center by an underground concourse.

 

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of endometrial cancer.

There is no registration fee for this event. For the in-person symposium in Washington, DC, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2024 ONS Congress.

IN-PERSON Registration for nurses and other healthcare providers

I am a practicing nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.